Skip to Content
scroll

Telix Pharma Ltd (TLX)

ASX.TLX $15.37

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

LEARN MORE

TLX $15.37

20 MINUTE DELAYED

TODAY

3.85 %

1 YEAR RETURN

0.00%

VOLUME

1,216,593

DIV YIELD

0%

PE RATIO

919.25

52 WEEK RANGE

8.20

15.60

ANALYSIS

i

SHARE PRICE ACTIVITY
Last (Price)

15.37

Change

0.57 (3.85)

Bid / Ask

15.28 - 15.39

Volume

1,216,593

Turnover

18,312,642

Open

15.39

Day Range

14.42 - 15.40

VWAP

15.05

Prev Close

14.80

Last Trade

20/05 4:10pm (AEST)

i

KEY INFORMATION
Sector

Healthcare

Shares Issued

247,357,796

NTA/Share

0.00

Last Dividend

0.00

Dividend Ex Date

0

Dividend Pay Date

0

i

BROKER CALLS

current

Mean

0.00

Target Price

0.00

i

CURRENT ()
Revenue

502.55

EBITDA

58.44

Profit

5.21

Earnings Per Share (EPS)

0

Dividend Per Share (DPS)

0

Yield %

0.00

Market Cap

0

Price to Earnings Ratio (P/E)

919.25

i

TARGET PRICE FORECAST

i

ESTIMATES ()
Revenue

738.40

EBITDA

112.99

Profit

55.07

Earnings Per Share (EPS)

0.17

Dividend Per Share (DPS)

0.00

i

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.00

Lt Growth Rate

0.00

Recommendation ()

0.00
OPINION
ACTION
image description

Business Summary

Telix Pharmaceuticals Limited is a radiopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) to treat cancer. In MTR therapy, a radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The radioactive payload can either be diagnostic (for imaging) or therapeutic, or both. Its lead programs include TLX591-CDx (Illuccix) / TLX591 for diagnosis and treatment of metastatic castrate-resistant prostate cancer, TLX250-CDx/TLX250 for diagnosis and treatment of renal (kidney) cancer, TLX101-CDx / TLX101 for diagnosis and treatment of glioblastoma (brain cancer), and TLX66-CDx (Scintimun) / TLX66 for the treatment of bone marrow conditioning and rare diseases.

image description

Only available to Members

Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing. Click here
Back to top